TY - JOUR
T1 - Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries
T2 - An expert panel discussion
AU - Santos, Raul D.
AU - Lorenzatti, Alberto
AU - Corral, Pablo
AU - Nogueira, Juan Patricio
AU - Cafferata, Alberto M.
AU - Aimone, Daniel
AU - Lourenço, Charles M.
AU - Izar, Maria Cristina
AU - Lima, Josivan G.
AU - Lottenberg, Ana Maria
AU - Alonso, Rodrigo
AU - Garay, Karla
AU - Morales, Alvaro Ruiz
AU - Vargas-Uricoechea, Hernando
AU - Peña, Christian A.Colón
AU - Roman-González, Alejandro
N1 - Publisher Copyright:
© 2021 National Lipid Association
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels due to impaired clearance of chylomicrons from plasma. This paper is the result of a panel discussion with Latin American specialists who raised the main issues on diagnosis and management of FCS in their countries. Overall FCS is diagnosed late on the course of the disease, is characterized by heterogeneity on the occurrence of pancreatitis, and remains a long time in care of different specialists until reaching a lipidologist. Pancreatitis and secondary diabetes are frequently seen, often due to late diagnosis and inadequate care. Molecular diagnosis is unusual; however, loss of function variants on the lipoprotein lipase gene are apparently the most frequent etiology. A founder effect of the glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 gene has been described in the northeast of Brazil. Low awareness of the disease amongst health professionals contributes to inadequate care and an inadequate patient journey.
AB - Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels due to impaired clearance of chylomicrons from plasma. This paper is the result of a panel discussion with Latin American specialists who raised the main issues on diagnosis and management of FCS in their countries. Overall FCS is diagnosed late on the course of the disease, is characterized by heterogeneity on the occurrence of pancreatitis, and remains a long time in care of different specialists until reaching a lipidologist. Pancreatitis and secondary diabetes are frequently seen, often due to late diagnosis and inadequate care. Molecular diagnosis is unusual; however, loss of function variants on the lipoprotein lipase gene are apparently the most frequent etiology. A founder effect of the glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 gene has been described in the northeast of Brazil. Low awareness of the disease amongst health professionals contributes to inadequate care and an inadequate patient journey.
KW - Clinical phenotype
KW - FCS
KW - Familial chylomicronemia syndrome
KW - Hypertriglyceridemia
UR - http://www.scopus.com/inward/record.url?scp=85121125122&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2021.10.004
DO - 10.1016/j.jacl.2021.10.004
M3 - Review article
C2 - 34920815
AN - SCOPUS:85121125122
SN - 1933-2874
VL - 15
SP - 620
EP - 624
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 5
ER -